Arbutus Swings to $59.1M Third-Quarter Profit
ABUS is trading near its 52-week low of $3.5 (6.0% above the low) on light trading volume (0.3× avg).
Summary
Arbutus posted $59.1M of third-quarter net income, a sharp swing from the $5.1M net loss it reported for Q2 2026, with earnings of 30c per share on revenue of $299,000. The profit lands after a transformative stretch: the company bought back 46M shares at $5.00 each in its $230M Dutch auction, retiring roughly 23% of shares outstanding, and the FDA lifted the clinical hold on its AB-101 hepatitis B program in late October. With the buyback shrinking the share count and the AB-101 IND reopened, the balance sheet and pipeline both look different than they did a quarter ago. The headline gives no cash balance, so the quality of the $59.1M — one-time items versus recurring — is not yet clear.
At the time of this announcement, ABUS was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $737M. The 52-week trading range was $3.50 to $5.45. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.